An easy, rapid and objective mathematical method to identify fatty acid synthase (oncogenic antigen-519) modulators with potential anticancer value

Ruth Lupu, Ramón Colomer, Javier A. Menéndez

Research output: Contribution to journalArticle

Abstract

Fatty acid synthase (FASN) is a novel druggable target for metabolically treating and preventing human malignancies. We envisioned that if loss of sensitivity to C75 (a slow-binding FASN inhibitor) occurs in parallel with loss of FASN expression and/or activity, a mathematical assessment of the nature of the interaction between investigational FASN modulators and C75 may predict the ability of experimental compounds to regulate FASN. We statistically compared the arithmetical sums of the anti-proliferative effects obtained when FASN modulators and C75 were used as single agents to those observed experimentally when agents were actually combined in a sequential schedule (i.e., FASN modulator→C75). A reduced sensitivity to C75 (antagonism) occurred when compounds down-regulated FASN activity/expression, while an enhanced C75 efficacy (synergism) was found following exposure to FASN up-regulators. This "C75-sensitivity test" might offer an easy, rapid and objective method to identify FASN inhibitors with potential anticancer value in human cancer.

Original languageEnglish (US)
Pages (from-to)219-226
Number of pages8
JournalClinical and Translational Oncology
Volume10
Issue number4
DOIs
StatePublished - 2008
Externally publishedYes

Fingerprint

Fatty Acid Synthases
Antigens
Neoplasms
Appointments and Schedules

Keywords

  • Breast cancer
  • Fatty acid synthase
  • Fatty acids
  • Metabolism

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

An easy, rapid and objective mathematical method to identify fatty acid synthase (oncogenic antigen-519) modulators with potential anticancer value. / Lupu, Ruth; Colomer, Ramón; Menéndez, Javier A.

In: Clinical and Translational Oncology, Vol. 10, No. 4, 2008, p. 219-226.

Research output: Contribution to journalArticle

@article{964ee23b6bd3487a9c01d7cb15f6ef2d,
title = "An easy, rapid and objective mathematical method to identify fatty acid synthase (oncogenic antigen-519) modulators with potential anticancer value",
abstract = "Fatty acid synthase (FASN) is a novel druggable target for metabolically treating and preventing human malignancies. We envisioned that if loss of sensitivity to C75 (a slow-binding FASN inhibitor) occurs in parallel with loss of FASN expression and/or activity, a mathematical assessment of the nature of the interaction between investigational FASN modulators and C75 may predict the ability of experimental compounds to regulate FASN. We statistically compared the arithmetical sums of the anti-proliferative effects obtained when FASN modulators and C75 were used as single agents to those observed experimentally when agents were actually combined in a sequential schedule (i.e., FASN modulator→C75). A reduced sensitivity to C75 (antagonism) occurred when compounds down-regulated FASN activity/expression, while an enhanced C75 efficacy (synergism) was found following exposure to FASN up-regulators. This {"}C75-sensitivity test{"} might offer an easy, rapid and objective method to identify FASN inhibitors with potential anticancer value in human cancer.",
keywords = "Breast cancer, Fatty acid synthase, Fatty acids, Metabolism",
author = "Ruth Lupu and Ram{\'o}n Colomer and Men{\'e}ndez, {Javier A.}",
year = "2008",
doi = "10.1007/s12094-008-0185-x",
language = "English (US)",
volume = "10",
pages = "219--226",
journal = "Clinical and Translational Oncology",
issn = "1699-048X",
publisher = "Springer-Verlag Italia",
number = "4",

}

TY - JOUR

T1 - An easy, rapid and objective mathematical method to identify fatty acid synthase (oncogenic antigen-519) modulators with potential anticancer value

AU - Lupu, Ruth

AU - Colomer, Ramón

AU - Menéndez, Javier A.

PY - 2008

Y1 - 2008

N2 - Fatty acid synthase (FASN) is a novel druggable target for metabolically treating and preventing human malignancies. We envisioned that if loss of sensitivity to C75 (a slow-binding FASN inhibitor) occurs in parallel with loss of FASN expression and/or activity, a mathematical assessment of the nature of the interaction between investigational FASN modulators and C75 may predict the ability of experimental compounds to regulate FASN. We statistically compared the arithmetical sums of the anti-proliferative effects obtained when FASN modulators and C75 were used as single agents to those observed experimentally when agents were actually combined in a sequential schedule (i.e., FASN modulator→C75). A reduced sensitivity to C75 (antagonism) occurred when compounds down-regulated FASN activity/expression, while an enhanced C75 efficacy (synergism) was found following exposure to FASN up-regulators. This "C75-sensitivity test" might offer an easy, rapid and objective method to identify FASN inhibitors with potential anticancer value in human cancer.

AB - Fatty acid synthase (FASN) is a novel druggable target for metabolically treating and preventing human malignancies. We envisioned that if loss of sensitivity to C75 (a slow-binding FASN inhibitor) occurs in parallel with loss of FASN expression and/or activity, a mathematical assessment of the nature of the interaction between investigational FASN modulators and C75 may predict the ability of experimental compounds to regulate FASN. We statistically compared the arithmetical sums of the anti-proliferative effects obtained when FASN modulators and C75 were used as single agents to those observed experimentally when agents were actually combined in a sequential schedule (i.e., FASN modulator→C75). A reduced sensitivity to C75 (antagonism) occurred when compounds down-regulated FASN activity/expression, while an enhanced C75 efficacy (synergism) was found following exposure to FASN up-regulators. This "C75-sensitivity test" might offer an easy, rapid and objective method to identify FASN inhibitors with potential anticancer value in human cancer.

KW - Breast cancer

KW - Fatty acid synthase

KW - Fatty acids

KW - Metabolism

UR - http://www.scopus.com/inward/record.url?scp=51649108891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51649108891&partnerID=8YFLogxK

U2 - 10.1007/s12094-008-0185-x

DO - 10.1007/s12094-008-0185-x

M3 - Article

C2 - 18411195

AN - SCOPUS:51649108891

VL - 10

SP - 219

EP - 226

JO - Clinical and Translational Oncology

JF - Clinical and Translational Oncology

SN - 1699-048X

IS - 4

ER -